Skip to content

Jazz Pharmaceuticals JAZZ Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$57.3M+2,457%
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Jazz Pharmaceuticals (JAZZ) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $32.9M in Q1 2026.
How has Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options increased by 186.1% year-over-year, from $11.5M to $32.9M.
What is the long-term trend for Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a -5.5% compound annual growth rate (CAGR), from $135.26M to $107.86M.
What does proceeds from issuance of shares under incentive and share based compensation plans including stock options mean?
Cash received from employees buying company stock through incentive plans.
How do you interpret proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Higher proceeds suggest increased employee participation in equity plans or higher levels of option exercises.
How does proceeds from issuance of shares under incentive and share based compensation plans including stock options compare across companies?
Common in companies with broad-based employee equity ownership.